Burjeel Holdings and US-based Northwell Health To Launch Neuroscience Institute in UAE

The ‘Dr. Najjar Neuroscience Institute’ will be headed by globally renowned Neurologist Dr. Souhel Najjar, who was featured in the best-selling novel and Netflix film “Brain on Fire”, to provide world-class specialized neurological care for people across the region.

As part of its ongoing efforts to bring complex care and to increase the flow of international patients to the UAE, Burjeel Holdings (“Burjeel” or “the Group”), one of the largest healthcare services providers in the MENA, has joined hands with Northwell Health, the largest healthcare provider in New York State, to launch a highly advanced Neuroscience Institute in Abu Dhabi.

The Neuroscience Institute will be located at Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, and will provide state-of-the-art care for adult and pediatric patients with neurological disorders, including autoimmune brain disorders, epilepsy, Parkinson’s and movement disorders, pediatric neurology, and multiple sclerosis. The collaboration between Burjeel Holdings and Northwell Health will enable the transfer of knowledge and expertise between the two organizations to deliver the best possible patient care.

World-renowned neurologist Dr. Souhel Najjar, professor and chairperson of the Department of Neurology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and executive director and senior vice president of the Northwell Health Neurology Service Line, will head the Institute in Abu Dhabi.

Dr. Souhel Najjar commented: “Northwell Health and Burjeel Holdings’ decision to build a neuroscience institute in the UAE demonstrates their synergistic culture of innovation and commitment to bring advanced, innovative, and compassionate neurological care to the UAE and the entire Middle East. On a personal level, I am proud of this relationship as it allows me to bring my Northwell Health family closer to the beloved UAE.”

Burjeel Holdings and Northwell Health formalized the establishment of the Dr. Najjar Neuroscience Institute at a ceremony held in New York at the Northwell Health corporate headquarters in Manhattan. The ceremony was attended by Dr. Shamsheer Vayalil, founder and chairman of Burjeel Holdings; Mr. John Sunil, CEO, Burjeel Holdings; Dr. Mohan Chellappa, non-executive director, Burjeel Holdings; Michael Dowling, president and CEO, Northwell Health; Dr. Souhel Najjar, SVP and executive director of the Neurology Service Line, Northwell Health; Dinelia Ortiz, vice president, Neurology Service Line, Northwell Health; Serena Najjar, senior project manager, Neurology Global Patient Services, Northwell Health; Kevin Beiner, SVP and regional executive director western region, Northwell Health.

Michael J. Dowling said: “This collaboration is an exciting opportunity to deliver world-class care to the communities of Abu Dhabi. Dr. Najjar has long been an example of clinical excellence for our health system and we are incredibly proud to see his team’s services offered across the globe.”

John Sunil, CEO, Burjeel Holdings added: “The partnership is another important step in the Burjeel Holdings’ commitment to delivering unmatched healthcare excellence in the region and greatly improving patient outcomes. The collaboration with Northwell Health and Dr. Najjar aligns with the Group’s endeavors to provide complex care and access to the newest treatments and technologies for patients across the region.”

Northwell Health’s Neurology Service Line is a regional and international destination for neurological care, committed to improving patient outcomes and driving innovation. Patients from all over the world can receive premier treatments for a wide spectrum of neurological disorders from renowned experts in the field.

Burjeel Medical City is a 400-bed leading quaternary care facility with cutting-edge medical technology and employing internationally recognized and published physicians. The Neuroscience Institute at the hospital will be supported by state-of-the-art medical technology and an international team of experts certified by top global medical boards.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”